Cargando…

Effect of meal timing on pharmacokinetics and pharmacodynamics of tegoprazan in healthy male volunteers

ABSTRACT: Tegoprazan, a novel potassium‐competitive acid blocker, is used to treat acid‐related diseases. However, there is no information on the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of the marketed dosage of tegoprazan under various meal timings in a fed and fasted state. The stud...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoon, Deok Y., Sunwoo, Jung, Shin, Naree, Kim, Ah R., Kim, Bongtae, Song, Geun S., Jang, In‐Jin, Lee, SeungHwan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8212751/
https://www.ncbi.nlm.nih.gov/pubmed/33382926
http://dx.doi.org/10.1111/cts.12958
_version_ 1783709699373268992
author Yoon, Deok Y.
Sunwoo, Jung
Shin, Naree
Kim, Ah R.
Kim, Bongtae
Song, Geun S.
Jang, In‐Jin
Lee, SeungHwan
author_facet Yoon, Deok Y.
Sunwoo, Jung
Shin, Naree
Kim, Ah R.
Kim, Bongtae
Song, Geun S.
Jang, In‐Jin
Lee, SeungHwan
author_sort Yoon, Deok Y.
collection PubMed
description ABSTRACT: Tegoprazan, a novel potassium‐competitive acid blocker, is used to treat acid‐related diseases. However, there is no information on the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of the marketed dosage of tegoprazan under various meal timings in a fed and fasted state. The study aimed to assess the effect of meal timing on PKs and PDs of tegoprazan 50 mg after a single administration in healthy male subjects. An open‐label, single‐dose, three‐treatment, three‐period crossover study was conducted. A total of 12 subjects were orally administered a single dose of tegoprazan 50 mg among various conditions: in a fasted state, at 30 min before or 30 min after a high‐fat meal. PK parameters were estimated by the noncompartmental method. Continuous 24‐h intragastric pH monitoring was done for PD analysis. The PKs and PDs of tegoprazan were compared among the various meal timings. Compared with the fasting condition, the PK profile of tegoprazan was similar when administered 30 min before a high‐fat meal; however, delayed absorption with similar systemic exposure was observed when administered 30 min after a high‐fat meal. The magnitude of acid suppression evaluated through the PD parameters increased when administered 30 min after a high‐fat meal compared with fasting the condition and when administered 30 min before a high‐fat meal. However, the increased difference in acid suppression was not clinically significant. Meal timing had no clinically significant effect on the PKs and PDs of tegoprazan 50 mg. Therefore, the marketed dosage of tegoprazan could be administered regardless of the meal timing. STUDY HIGHLIGHTS: WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC? WHAT QUESTION DID THIS STUDY ADDRESS? WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE? HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE? In the actual clinical environment, patients take medicine under various fed conditions. This study evaluated the effect of food on PKs and PDs of tegoprazan in various clinical conditions, and provided the important information about meal timing when administering tegoprazan.
format Online
Article
Text
id pubmed-8212751
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-82127512021-06-25 Effect of meal timing on pharmacokinetics and pharmacodynamics of tegoprazan in healthy male volunteers Yoon, Deok Y. Sunwoo, Jung Shin, Naree Kim, Ah R. Kim, Bongtae Song, Geun S. Jang, In‐Jin Lee, SeungHwan Clin Transl Sci Research ABSTRACT: Tegoprazan, a novel potassium‐competitive acid blocker, is used to treat acid‐related diseases. However, there is no information on the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of the marketed dosage of tegoprazan under various meal timings in a fed and fasted state. The study aimed to assess the effect of meal timing on PKs and PDs of tegoprazan 50 mg after a single administration in healthy male subjects. An open‐label, single‐dose, three‐treatment, three‐period crossover study was conducted. A total of 12 subjects were orally administered a single dose of tegoprazan 50 mg among various conditions: in a fasted state, at 30 min before or 30 min after a high‐fat meal. PK parameters were estimated by the noncompartmental method. Continuous 24‐h intragastric pH monitoring was done for PD analysis. The PKs and PDs of tegoprazan were compared among the various meal timings. Compared with the fasting condition, the PK profile of tegoprazan was similar when administered 30 min before a high‐fat meal; however, delayed absorption with similar systemic exposure was observed when administered 30 min after a high‐fat meal. The magnitude of acid suppression evaluated through the PD parameters increased when administered 30 min after a high‐fat meal compared with fasting the condition and when administered 30 min before a high‐fat meal. However, the increased difference in acid suppression was not clinically significant. Meal timing had no clinically significant effect on the PKs and PDs of tegoprazan 50 mg. Therefore, the marketed dosage of tegoprazan could be administered regardless of the meal timing. STUDY HIGHLIGHTS: WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC? WHAT QUESTION DID THIS STUDY ADDRESS? WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE? HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE? In the actual clinical environment, patients take medicine under various fed conditions. This study evaluated the effect of food on PKs and PDs of tegoprazan in various clinical conditions, and provided the important information about meal timing when administering tegoprazan. John Wiley and Sons Inc. 2021-01-21 2021-05 /pmc/articles/PMC8212751/ /pubmed/33382926 http://dx.doi.org/10.1111/cts.12958 Text en © 2020 The Authors. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of the American Society for Clinical Pharmacology and Therapeutics. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Research
Yoon, Deok Y.
Sunwoo, Jung
Shin, Naree
Kim, Ah R.
Kim, Bongtae
Song, Geun S.
Jang, In‐Jin
Lee, SeungHwan
Effect of meal timing on pharmacokinetics and pharmacodynamics of tegoprazan in healthy male volunteers
title Effect of meal timing on pharmacokinetics and pharmacodynamics of tegoprazan in healthy male volunteers
title_full Effect of meal timing on pharmacokinetics and pharmacodynamics of tegoprazan in healthy male volunteers
title_fullStr Effect of meal timing on pharmacokinetics and pharmacodynamics of tegoprazan in healthy male volunteers
title_full_unstemmed Effect of meal timing on pharmacokinetics and pharmacodynamics of tegoprazan in healthy male volunteers
title_short Effect of meal timing on pharmacokinetics and pharmacodynamics of tegoprazan in healthy male volunteers
title_sort effect of meal timing on pharmacokinetics and pharmacodynamics of tegoprazan in healthy male volunteers
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8212751/
https://www.ncbi.nlm.nih.gov/pubmed/33382926
http://dx.doi.org/10.1111/cts.12958
work_keys_str_mv AT yoondeoky effectofmealtimingonpharmacokineticsandpharmacodynamicsoftegoprazaninhealthymalevolunteers
AT sunwoojung effectofmealtimingonpharmacokineticsandpharmacodynamicsoftegoprazaninhealthymalevolunteers
AT shinnaree effectofmealtimingonpharmacokineticsandpharmacodynamicsoftegoprazaninhealthymalevolunteers
AT kimahr effectofmealtimingonpharmacokineticsandpharmacodynamicsoftegoprazaninhealthymalevolunteers
AT kimbongtae effectofmealtimingonpharmacokineticsandpharmacodynamicsoftegoprazaninhealthymalevolunteers
AT songgeuns effectofmealtimingonpharmacokineticsandpharmacodynamicsoftegoprazaninhealthymalevolunteers
AT janginjin effectofmealtimingonpharmacokineticsandpharmacodynamicsoftegoprazaninhealthymalevolunteers
AT leeseunghwan effectofmealtimingonpharmacokineticsandpharmacodynamicsoftegoprazaninhealthymalevolunteers